Financial Survey: TNF Pharmaceuticals (NASDAQ:TNFA) and Alpha Teknova (NASDAQ:TKNO)

TNF Pharmaceuticals (NASDAQ:TNFA) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Volatility & Risk

TNF Pharmaceuticals has a beta of 2.32, suggesting that its stock price is 132% more volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Profitability

This table compares TNF Pharmaceuticals and Alpha Teknova’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
TNF Pharmaceuticals	N/A	-180.71%	-84.27%
Alpha Teknova	-87.17%	-35.30%	-24.52%

Institutional and Insider Ownership

9.6% of TNF Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 1.2% of TNF Pharmaceuticals shares are owned by company insiders. Comparatively, 15.2% of Alpha Teknova shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for TNF Pharmaceuticals and Alpha Teknova, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TNF Pharmaceuticals	0	0	0	0	0.00
Alpha Teknova	0	0	2	0	3.00

Alpha Teknova has a consensus target price of $8.50, indicating a potential upside of 45.05%. Given Alpha Teknova’s stronger consensus rating and higher probable upside, analysts plainly believe Alpha Teknova is more favorable than TNF Pharmaceuticals.

Valuation & Earnings

This table compares TNF Pharmaceuticals and Alpha Teknova”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TNF Pharmaceuticals	N/A	N/A	-$4.00 million	N/A	N/A
Alpha Teknova	$37.75 million	8.30	-$36.78 million	($0.59)	-9.93

TNF Pharmaceuticals has higher earnings, but lower revenue than Alpha Teknova.

Summary

Alpha Teknova beats TNF Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

About TNF Pharmaceuticals

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

About Alpha Teknova

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.